HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SIBN
SI-BONE, Inc.
SIBN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SIBN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SIBN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SIBN PE Valuation
SIBN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SIBN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
SIBN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SIBN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.31 | +$0.19 |
| Q2 2026 | -$0.34 | +$0.21 |
| Q1 2026 | -$0.39 | +$0.24 |
| Q4 2025 | -$0.44 | +$0.31 |
| Q3 2025 | -$0.50 | +$0.41 |
| Q2 2025 | -$0.55 | +$0.45 |
| Q1 2025 | -$0.63 | +$0.45 |
| Q4 2024 | -$0.75 | +$0.38 |
SIBN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SIBN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SIBN on profitability, with a higher operating margin.
SIBN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.7M | +14% |
| Q2 2026 | $56M | +15% |
| Q1 2026 | $52.6M | +11% |
| Q4 2025 | $56.3M | +15% |
| Q3 2025 | $48.7M | +21% |
| Q2 2025 | $48.6M | +22% |
| Q1 2025 | $47.3M | +25% |
| Q4 2024 | $49M | +26% |
SIBN's revenue has grown year over year every quarter since late 2020: $56M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.8% | +3.3 points |
| Q2 2026 | -8.6% | +5.8 points |
| Q1 2026 | -9.7% | +6.1 points |
| Q4 2025 | -4.4% | +6.8 points |
| Q3 2025 | -11% | +7.9 points |
| Q2 2025 | -14% | +11 points |
| Q1 2025 | -16% | +16 points |
| Q4 2024 | -11% | +21 points |
SIBN's operating margin was −7.8% last quarter, up 3.3 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SIBN on cash generation, producing positive trailing cash flow while its opponent burns cash.
SIBN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$427K | +$193K |
| Q2 2026 | -$768K | +$1.2M |
| Q1 2026 | -$3.4M | +$3.5M |
| Q4 2025 | $440K | +$1.5M |
| Q3 2025 | -$620K | +$2.1M |
| Q2 2025 | -$1.9M | +$7.5M |
| Q1 2025 | -$7M | +$2.7M |
| Q4 2024 | -$1.1M | +$2.3M |
SIBN has burned cash in almost every quarter: −$4M over the past year, against −$11M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SIBN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SIBN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +422K shares |
| 1 year | +4% | +1.7M shares |
| 3 years | +12% | +4.6M shares |
| 5 years | +35% | +11.6M shares |
| Available history | +82% | +20.2M shares |
SIBN has 45M diluted shares, up 4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SIBN Net Leverage
SIBN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SIBN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.9 | Overbought |
| Stochastic | 76.7 | Neutral |
SIBN's weekly RSI is 75 (overbought) and its Stochastic is 77 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SIBN PE vs Healthcare Sector
SIBN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SIBN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.9 | 16% above |
| 20 week MA | $19.3 | 25% above |
| 50 week MA | $17.1 | 41% above |
| 100 week MA | $16.6 | 45% above |
| 200 week MA | $17.5 | 38% above |
SIBN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SIBN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.1 | $30.3 | +43% |
| 2021 | $30.3 | $21.9 | -28% |
| 2022 | $21.9 | $11.8 | -46% |
| 2023 | $11.8 | $21.0 | +78% |
| 2024 | $21.0 | $13.7 | -35% |
| 2025 | $13.7 | $20.4 | +48% |
| 2026 YTD | $20.4 | $24.1 | +19% |
SIBN has the edge over HIMS on returns for 2026, with the stronger performance.